Brain Imaging and Retreatment Study of Persistent Lyme Disease

PET and MRI Imaging of Persistent Lyme Encephalopathy

The purpose of this study is to determine whether patients with persistent memory problems after Lyme disease benefit from an additional longer course of IV antibiotic therapy; to use modern brain imaging technology to determine whether the problem in the central nervous system is primarily one of poor blood flow or one of impaired nerve cell functioning; and to try to identify biological markers prior to treatment that will identify patients who are more or less likely to respond to the study treatment.

Study Overview

• Status: Completed
• Conditions: Lyme Disease; Lyme Neuroborreliosis
• Intervention / Treatment: Drug: ceftriaxone

Detailed Description

Some people with a history of Lyme disease continue to have problems despite having received "textbook duration" antibiotic therapy. When memory, attention, or thinking problems persist, the syndrome is called persistent Lyme disease (PLD). This study seeks to answer critical scientific questions about the treatment and cause of PLD symptoms.

This 24-week treatment study will evaluate each patient's response to treatment using neuropsychological testing and state-of-the-art brain imaging. The brain tests include neuropsychological testing of memory and attention, brain imaging (MRI and PET scans) to look at blood flow in the brain and nerve cell structure and metabolism, a neurological exam, and studies of the fluid that surrounds the brain (cerebrospinal fluid). The treatment involves 10 weeks of either intravenous antibiotic called ceftriaxone (also known as Rocephin) or intravenous placebo (inactive substance). After the first visit to Columbia Presbyterian Medical Center, the remaining treatments will be done in the patient's home. Patients will be screened over the phone and in person to confirm study eligibility.

• Study Type: Interventional
• Enrollment: 65
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10032
      • Columbia Presbyterian Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Eligible participants must:

• Be 18-65 years old
• Have persistent problems with memory, verbal fluency, or attention after having contracted Lyme disease.
• Be able to travel to New York for 4-5 evaluations over the course of one year. Travel costs for participants in need may be partially or fully reimbursable.
• Have had a history of well-documented Lyme disease using the CDC's clinical criteria and a current positive IgG Western blot or PCR.
• Have received, at some point in the past at least 3 weeks of IV antibiotic therapy for Lyme disease.

Exclusion Criteria:

Ineligible from participation are people with the following:

• Other major medical or neurologic problems
• Smoke more than 10 cigarettes a day
• Uncontrolled high blood pressure
• Allergy to ceftriaxone (Rocephin)
• History of marked cocaine abuse

Twenty healthy subjects are also being sought for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized

Collaborators and Investigators

• Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
• Investigators: Principal Investigator: Brian Fallon, M.D., Columbia University, College of Physicians and Surgeons, Lyme Disease Research Program

Publications and helpful links

Helpful Links

• Columbia's Lyme disease research studies website

Study record dates

Study Major Dates

• Study Start: December 1, 1999
• Primary Completion: December 7, 2022
• Study Completion: December 7, 2022

Study Registration Dates

• First Submitted: May 17, 2002
• First Submitted That Met QC Criteria: May 17, 2002
• First Posted (Estimate): May 20, 2002

Study Record Updates

• Last Update Posted (Estimate): December 7, 2005
• Last Update Submitted That Met QC Criteria: December 6, 2005
• Last Verified: December 1, 2005

More Information

Terms related to this study

• Keywords: Lyme disease; neurologic Lyme disease; ceftriaxone; Rocephin; PET scans; Lyme encephalopathy; neuroborreliosis; borreliosis
• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Infections; Central Nervous System Infections; Vector Borne Diseases; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Central Nervous System Bacterial Infections; Tick-Borne Diseases; Borrelia Infections; Spirochaetales Infections; Lyme Disease; Lyme Neuroborreliosis; Anti-Infective Agents; Anti-Bacterial Agents; Ceftriaxone
• Other Study ID Numbers: R01NS038636 (U.S. NIH Grant/Contract)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No